News

Filter

Current filters:

Cardio-vascular

501 to 510 of 97217 results

New Phase IIIa data further demonstrate benefits of liraglutide in obesity

04-11-2014

Positive new data from the Phase IIIa SCALE Obesity and Prediabetes trial were presented today at Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearchSaxendaVictoza

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

Diabetes drugs could potentially reverse Alzheimer's damage, say UK researchers

04-11-2014

A new study has suggested that drugs currently being used to treat diabetes also have the potential to…

liraglutidelixisenatideNeurologicalNovo NordiskPharmaceuticalResearchSanofiUK

Dana-Farber Cancer Institute and Astellas in three-year collaboration on small molecule inhibitors

Dana-Farber Cancer Institute and Astellas in three-year collaboration on small molecule inhibitors

04-11-2014

Boston-based Dana-Farber Cancer Institute and Japanese drug major Astellas Pharma have entered into a…

AstellasOncologyPharmaceuticalResearchUSA

EGA and EBG see EMA latest biosimilars guidance as “important step forward”

EGA and EBG see EMA latest biosimilars guidance as “important step forward”

04-11-2014

The European Generic medicines Association (EGA) and the European Biosimilars Group (EBG), a sector group…

BiosimilarsEuropeGenericsRegulation

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

MedImmune to acquire company to strengthen focus on biomarkers in immuno-oncology

04-11-2014

MedImmune, a US subsidiary of Anglo-Swedish pharma major AstraZeneca has entered into an agreement to…

AstraZenecaDefiniensMedImmuneMergers & AcquisitionsOncologyPharmaceutical

IQWIG confirms an additional benefit of Eisai's Halaven

IQWIG confirms an additional benefit of Eisai's Halaven

04-11-2014

Following a benefit:cost re-assessment, the German Institute for Quality and Efficiency in Health Care…

EisaiGermanyHalavenOncologyPharmaceuticalPricingRegulation

Added benefit of Takeda’s Entyvio is not proven, says IQWiG

Added benefit of Takeda’s Entyvio is not proven, says IQWiG

04-11-2014

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products,…

EntyvioGastro-intestinalsGermanyPharmaceuticalPricingRegulationTakeda Pharmaceutical

AOP Orphan brings Thromboreductin to Russian market

04-11-2014

Austria-based rare diseases specialist AOP Orphan is expanding its sales area for Thromboreductin (anagrelide)…

AnagrelideAOP OrphanMarkets & MarketingPharmaceuticalRare diseasesRussiaThromboreductin

Pharming strengthens balance sheet with $20 million milestone from Salix

Pharming strengthens balance sheet with $20 million milestone from Salix

04-11-2014

Dutch biotech company Pharming Group says it has received a $20 million milestone payment from the USA’s…

BiotechnologyFinancialPharming GroupRare diseasesRuconestSalix Pharmaceuticals

501 to 510 of 97217 results

Back to top